MX2021002923A - (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso. - Google Patents

(r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso.

Info

Publication number
MX2021002923A
MX2021002923A MX2021002923A MX2021002923A MX2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A
Authority
MX
Mexico
Prior art keywords
trifluoromethoxy
piperazine
carboxylate
methyl
crystalline
Prior art date
Application number
MX2021002923A
Other languages
English (en)
Spanish (es)
Inventor
Jun Xu
Lianfeng Huang
Nancy Tsou
Nicole Suzanne White
Qun Zhang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021002923A publication Critical patent/MX2021002923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021002923A 2018-09-13 2019-09-12 (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso. MX2021002923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021002923A true MX2021002923A (es) 2021-09-08

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002923A MX2021002923A (es) 2018-09-13 2019-09-12 (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso.

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
KR20210057789A (ko) 2021-05-21
US11053199B2 (en) 2021-07-06
MA53607A (fr) 2021-12-22
EP4434583A2 (en) 2024-09-25
JP2022500441A (ja) 2022-01-04
HUE068147T2 (hu) 2024-12-28
KR102844245B1 (ko) 2025-08-11
ES2993173T3 (en) 2024-12-23
WO2020056105A9 (en) 2020-07-09
FI4434583T3 (fi) 2026-05-15
HRP20260757T1 (hr) 2026-08-14
EP4434583B1 (en) 2026-04-01
PL3849970T3 (pl) 2025-01-07
AU2019337623A1 (en) 2021-05-13
US20210363105A1 (en) 2021-11-25
RS68181B1 (sr) 2026-06-30
LT3849970T (lt) 2024-10-10
US20260062384A1 (en) 2026-03-05
US11680046B2 (en) 2023-06-20
PL4434583T3 (pl) 2026-07-20
DK4434583T5 (da) 2026-07-06
EP4434583A3 (en) 2024-11-20
SG11202102143RA (en) 2021-04-29
MY208901A (en) 2025-06-09
EP3849970A1 (en) 2021-07-21
CA3112200A1 (en) 2020-03-19
AU2019337623B2 (en) 2024-12-05
IL281276A (en) 2021-04-29
SMT202400369T1 (it) 2024-11-15
EP4768081A2 (en) 2026-07-01
EA202190511A1 (ru) 2021-07-05
EP3849970B1 (en) 2024-07-03
SMT202600252T1 (it) 2026-07-16
PT3849970T (pt) 2024-09-25
SI3849970T1 (sl) 2024-11-29
IL281276B2 (en) 2025-01-01
IL281276B1 (en) 2024-09-01
CN113227069B (zh) 2024-11-05
MY210363A (en) 2025-09-13
CL2021000596A1 (es) 2021-07-30
LT4434583T (lt) 2026-06-25
DK4434583T3 (da) 2026-06-15
PT4434583T (pt) 2026-06-11
US12410133B2 (en) 2025-09-09
US20200095201A1 (en) 2020-03-26
WO2020056105A1 (en) 2020-03-19
MA53607B1 (fr) 2025-05-30
RS65967B1 (sr) 2024-10-31
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
CN118530218A (zh) 2024-08-23
FI3849970T3 (fi) 2024-09-20
CO2021003295A2 (es) 2021-07-30
ES3072981T3 (en) 2026-07-07
US20230382861A1 (en) 2023-11-30
MA71839B1 (fr) 2026-05-26
CN113227069A (zh) 2021-08-06
BR112021004340A2 (pt) 2021-05-25
CN118561814A (zh) 2024-08-30
DK3849970T3 (da) 2024-09-30

Similar Documents

Publication Publication Date Title
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12018501877A1 (en) Substituted indole mcl-1 inhibitors
EP4279071A3 (en) Novel cannabinoid formulations
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
SG10201811384TA (en) Mnk inhibitors and methods related thereto
ZA202403308B (en) An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX393879B (es) Métodos de preparación de niraparib.
MY197519A (en) Notch pathway signaling inhibitor compounds
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
MY192425A (en) Polymorphs
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
PH12020550947A1 (en) Polymorphs
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
MX2023011687A (es) Formas y composiciones farmaceuticas de ivosidenib.
CA3073766A1 (en) Process for the preparation of tubulysins and intermediates thereof
SA521421375B1 (ar) عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها
JOP20200025A1 (ar) مركبات جديدة تنشط مسار Nrf2
MY210363A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
WO2019136310A3 (en) Novel compounds for the treatment of neurodegenerative diseases
AU2019248350A8 (en) Process for making sarecycline hydrochloride
MX2022005604A (es) Metodos para la preparacion de 3-bromo-1-(3-cloropiridin-2-il)-1h- pirazol-5-carboxilato de etilo.
WO2019151967A3 (en) Water-dispersible tablet formulations comprising deferasirox